ArticleCureus2025
Anti-neutrophil Cytoplasmic Antibody (ANCA)-Negative Pauci-Immune Crescentic Glomerulonephritis: A Case Series From a Tertiary Care Hospital in South India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPauci-immune crescentic glomerulonephritis (PICGN) is a critical form of renal disease characterized by a swift deterioration in kidney function and crescent formation in glomeruli, usually in the absence of notable immune deposits. While commonly associated with anti-neutrophil cytoplasmic antibodies (ANCAs), a subset of patients presents without detectable ANCA, complicating both diagnosis and management.
objectiveThis case series presents an overview of the clinical manifestations, laboratory parameters, biopsy findings, and therapeutic outcomes observed in individuals diagnosed with ANCA-negative PICGN through histological confirmation.
methodsThis series reviews seven retrospective cases of ANCA-negative PICGN managed at a tertiary hospital in South India, focusing on clinical presentation, investigations, renal biopsy findings, treatment strategies, and outcomes.
resultsAll seven patients exhibited acute kidney injury (AKI), significant proteinuria, and active urinary sediment. Inflammatory markers were elevated in all cases. Renal biopsies demonstrated 70-90% crescent formation with the absence of immune complex deposits. Serologic tests for ANCA, antinuclear antibody (ANA), and double-stranded DNA (dsDNA) were negative; complement levels remained within the normal limits. Three patients had identifiable urinary tract infections with Gram-negative organisms. Two patients developed pulmonary involvement. Each patient was treated with a combination of corticosteroids and cyclophosphamide, alongside supportive renal replacement therapy through dialysis. Four patients improved partially, one showed a slow response, while two succumbed during hospitalization.
conclusionANCA-negative PICGN represents a severe crescentic glomerulonephritis with significant diagnostic and therapeutic implications. Prompt renal biopsy and early immunosuppressive therapy are essential for renal salvage. Despite treatment, outcomes remain variable, emphasizing the need for heightened clinical suspicion and timely intervention. ANCA-negative PICGN is an aggressive glomerular disease. Renal biopsy is indispensable in seronegative cases of rapid renal deterioration. Due to its aggressive nature, this form of glomerular disease requires timely histopathological evaluation and the immediate initiation of immunosuppressive therapy, especially when autoimmune serology is negative. Although partial recovery is possible, mortality remains a concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.